HANK & LIN'S GROUP

Publishcation：

1. Wang, Guochang, Linlin Li, Jie Zang, Haiyan Hong, Lin Zhu, Hank F. Kung, and Zhaohui Zhu. "Head-to-Head Comparison of ⁶⁸Ga-P16-093 and ⁶⁸Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer: A Pilot Study."Clinical Nuclear Medicine(2023);48: 289–295.
2. Bahler, Clinton D., Mark A. Green, Mark A. Tann, Jordan K. Swensson, Katrina Collins, David Alexoff, Hank Kung et al. "Assessing extra-prostatic extension for surgical guidance in prostate cancer: Comparing two PSMA-PET tracers with the standard-of-care." InUrologic Oncology: Seminars and Original Investigations, vol. 41, no. 1, pp. 48-e1. Elsevier, 2023.
3. Wang, Guochang, Linlin Li, Jiarou Wang, Jie Zang, Jingci Chen, Yu Xiao, Xinrong Fan, Lin Zhu, Hank F. Kung, and Zhaohui Zhu. "Head-to-head comparison of [⁶⁸Ga] Ga-P16-093 and 2-[¹⁸F] FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study."European Journal of Nuclear Medicine and Molecular Imaging 50(2023):1499–1509
4. Wang, Guochang, Linlin Li, Ming Zhu, Jiarou Wang, Rongxi Wang, Weigang Yan, Lin Zhu, Hank F Kung, Zhaohui Zhu. "A prospective head‑to‑head comparison of [⁶⁸Ga]Ga-P16-093 and [⁶⁸Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer". European Journal of Nuclear Medicine and Molecular Imaging 50, 3126–3136 (2023)
   
5. Lee, Hwan, Joshua S. Scheuermann, Anthony J. Young, Robert K. Doot, Margaret E. Daube-Witherspoon, Erin K. Schubert, Matthew A. Fillare et al. "Preliminary Evaluation of ⁶⁸Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer." Molecular Imaging and Biology (2022): 1-11.
6. Wang, Guochang, Haiyan Hong, Jie Zang, Qingxing Liu, Yuanyuan Jiang, Xinrong Fan, Zhaohui Zhu, Lin Zhu, and Hank F. Kung. "Head-to-head comparison of [⁶⁸Ga]Ga-P16-093 and [⁶⁸Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients." European journal of nuclear medicine and molecular imaging 49, no. 3 (2022): 1052-1062.
7. Green, Mark A., Gary D. Hutchins, Clinton D. Bahler, Mark Tann, Carla J. Mathias, Wendy Territo, Justin Sims et al. "[⁶8Ga] Ga-P16-093 as a PSMA-targeted PET radiopharmaceutical for detection of cancer: initial evaluation and comparison with [⁶⁸Ga] Ga-PSMA-11 in prostate cancer patients presenting with biochemical recurrence." Molecular imaging and biology 22, no. 3 (2020): 752-763.
8. Hong, Haiyan, Guochang Wang, Karl Ploessl, Zhihao Zha, Jie Zang, Zhaohui Zhu, Lin Zhu, and Hank F. Kung. "Kit-based preparation of [⁶⁸Ga] Ga-P16-093 (PSMA-093) using different commercial ⁶⁸Ge/⁶⁸Ga generators." Nuclear Medicine and Biology 106 (2022): 1-9.
9. Zha, Z., et al. "Synthesis and evaluation of a novel urea-based, ⁶⁸Ga-complex for imaging PSMA binding in tumor". Nuclear Medicine and Biology, 2018, 59, 36–47.

Meeting Abstracts：

1. Wang J, Li L, Wang R, Zhou Z, Zhu L, Yan W, Kung H, Zhu Z. [⁶⁸Ga]Ga-P16-093 Diagnostic Performance in Newly Diagnosed Prostate Cancer-Histopathologic Correlation. Journal of Nuclear MedicineJune 2024,65(supplement 2)241986
2. Territo W, Hutchins G, Clint B, Tann M, Collins K, Mathias C, Alexoff D, Kung H, Green M. Selection of Optimal Quantification Metric in Static Prostate Cancer Imaging with the PSMA-targeted [⁶⁸Ga]Ga-PSMA-11 and [⁶⁸Ga]Ga-P16-093 PET Radiopharmaceuticals. Journal of Nuclear MedicineJune 2024,65(supplement 2)242185;
3. Bahler, Clinton, Mark Green, Mark Tann, Katrina Collins, Jordan Swensson, Eric Brocken, Liang Cheng et al. "PD27-01 PREDICTING EXTRA-PROSTATIC EXTENSION (EPE) FOR SURGICAL GUIDANCE IN PROSTATE CANCER: A COMPARISON OF BIOPSY PATHOLOGY, MULTIPARAMETRIC MRI, AND PSMA-PET." The Journal of Urology 207, no. Supplement 5 (2022): e493.
4. Green, Mark, Clint Bahler, Mark Tann, Gary Hutchins, Carla Mathias, Wendy Territo, Rumeal Whaley et al. "PSMA-targeted PET with [⁶⁸Ga]Ga-P16-093: Initial evaluation in intermediate-risk and high-risk prostate cancer patients prior to prostatectomy." Journal of Nuclear Medicine May 2020, 61 (supplement 1) 192.
5. Whaley, Liang Cheng, David Alexoff, and Hank Kung. "PSMA-targeted PET with [⁶⁸Ga]Ga-P16-093: Assessment of potential role in surgical planning for patients with intermediate-risk and high-risk prostate cancer." Journal of Nuclear Medicine May 2020, 61 (supplement 1) 1252.